Efficacy and Safety of Switching from Ranibizumab to
Brolucizumab in Age-Related Macular Degeneration: Multicenter
Real-World Outcomes

J 2025

Efficacy and Safety of Switching from Ranibizumab to Brolucizumab in Age-Related Macular Degeneration: Multicenter Real-World Outcomes

HEJSEK, Libor; Michal HREVUS; Maria BUROVA; David BERAN; Zuzana CYZOVA et al.

Základní údaje

Originální název

Efficacy and Safety of Switching from Ranibizumab to Brolucizumab in Age-Related Macular Degeneration: Multicenter Real-World Outcomes

Autoři

HEJSEK, Libor; Michal HREVUS; Maria BUROVA; David BERAN; Zuzana CYZOVA; Martin PENCAK; Tereza PAŘILOVÁ; Dana LILAKOVA a Miroslav VEITH

Vydání

CLINICAL OPHTHALMOLOGY, ALBANY, DOVE MEDICAL PRESS LTD, 2025

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Označené pro přenos do RIV

DOI

https://doi.org/10.2147/OPTH.S543921

UT WoS

001594078700001

Klíčová slova anglicky

wet age-related macular degeneration; anti-VEGF therapy; ranibizumab; brolucizumab; switch; real outcomes

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 7. 2. 2026 23:47, RNDr. BcA. Tereza Pařilová, DiS., MBA, Ph.D.

Anotace

V originále

Purpose To assess whether switching from ranibizumab (0.5 mg) to brolucizumab (6 mg) improves injection intervals, disease activity, and anatomical/functional outcomes in wet age-related macular degeneration (wAMD). Methods This multicenter retrospective study included patients aged >= 50 years with active wAMD, baseline visual acuity (VA) 35-70, lesion size <= 8 disc areas, and submacular hemorrhage <= 25%. All had prior ranibizumab and were switched to brolucizumab for suboptimal response. VA and central retinal thickness (CRT) were recorded at switch, 6, and 12 months. Injection counts before and after switching were analyzed. Safety was monitored for intraocular inflammation (IOI) and discontinuation. Results Seventy-nine eyes (75 patients) were enrolled; 66 eyes (60 patients, median age 75.0 years [IQR: 70.0-80.0]) completed 12 months. Patients received median 12.0 ranibizumab injections [IQR: 8.0-19.0] pre-switch and 5.0 brolucizumab injections [IQR: 4.0-6.0] post-switch. Median switch VA was 50.0 letters [IQR: 36.5-63.0]; CRT was 319.0 mu m [IQR: 258.0-393.0]. At 6 months, VA improved to 51.0 [IQR: 38.0-66.5] (p = 0.0001) and CRT decreased to 255.0 mu m [IQR: 216.0-298.0] (p < 0.00000001). At 12 months VA was 50.5 [IQR: 38.5-68.0] (p = 0.0004 vs baseline) and CRT 251.5 m [IQR: 207.5-282.5] (p < 0.0001). Adverse events included 6 IOI cases, with discontinuation in 9 eyes overall. Conclusion Switching to brolucizumab reduced CRT, modestly improved or stabilized VA, and decreased injection frequency with acceptable safety. Limitations include retrospective design, modest sample size, and exclusion of poor visual outcomes, potentially introducing selection bias.

Citovat

HEJSEK, Libor; Michal HREVUS; Maria BUROVA; David BERAN; Zuzana CYZOVA; Martin PENCAK; Tereza PAŘILOVÁ; Dana LILAKOVA a Miroslav VEITH. Efficacy and Safety of Switching from Ranibizumab to Brolucizumab in Age-Related Macular Degeneration: Multicenter Real-World Outcomes. Online. CLINICAL OPHTHALMOLOGY. ALBANY: DOVE MEDICAL PRESS LTD, 2025, roč. 19, s. 3729-3740. Dostupné z: https://doi.org/10.2147/OPTH.S543921.

@article{2546597,
   author = {Hejsek, Libor and Hrevus, Michal and Burova, Maria and Beran, David and Cyzova, Zuzana and Pencak, Martin and Pařilová, Tereza and Lilakova, Dana and Veith, Miroslav},
   article_location = {ALBANY},
   doi = {https://doi.org/10.2147/OPTH.S543921},
   keywords = {wet age-related macular degeneration; anti-VEGF therapy; ranibizumab; brolucizumab; switch; real outcomes},
   language = {eng},
   journal = {CLINICAL OPHTHALMOLOGY},
   title = {Efficacy and Safety of Switching from Ranibizumab to Brolucizumab in Age-Related Macular Degeneration: Multicenter Real-World Outcomes},
   volume = {19},
   year = {2025}
}

TY  - JOUR
ID  - 2546597
AU  - Hejsek, Libor - Hrevus, Michal - Burova, Maria - Beran, David - Cyzova, Zuzana - Pencak, Martin - Pařilová, Tereza - Lilakova, Dana - Veith, Miroslav
PY  - 2025
TI  - Efficacy and Safety of Switching from Ranibizumab to Brolucizumab in Age-Related Macular Degeneration: Multicenter Real-World Outcomes
JF  - CLINICAL OPHTHALMOLOGY
VL  - 19
SP  - 3729-3740
EP  - 3729-3740
PB  - DOVE MEDICAL PRESS LTD
KW  - wet age-related macular degeneration
KW  - anti-VEGF therapy
KW  - ranibizumab
KW  - brolucizumab
KW  - switch
KW  - real outcomes
N2  - Purpose To assess whether switching from ranibizumab (0.5 mg) to brolucizumab (6 mg) improves injection intervals, disease activity, and anatomical/functional outcomes in wet age-related macular degeneration (wAMD). Methods This multicenter retrospective study included patients aged >= 50 years with active wAMD, baseline visual acuity (VA) 35-70, lesion size <= 8 disc areas, and submacular hemorrhage <= 25%. All had prior ranibizumab and were switched to brolucizumab for suboptimal response. VA and central retinal thickness (CRT) were recorded at switch, 6, and 12 months. Injection counts before and after switching were analyzed. Safety was monitored for intraocular inflammation (IOI) and discontinuation. Results Seventy-nine eyes (75 patients) were enrolled; 66 eyes (60 patients, median age 75.0 years [IQR: 70.0-80.0]) completed 12 months. Patients received median 12.0 ranibizumab injections [IQR: 8.0-19.0] pre-switch and 5.0 brolucizumab injections [IQR: 4.0-6.0] post-switch. Median switch VA was 50.0 letters [IQR: 36.5-63.0]; CRT was 319.0 mu m [IQR: 258.0-393.0]. At 6 months, VA improved to 51.0 [IQR: 38.0-66.5] (p = 0.0001) and CRT decreased to 255.0 mu m [IQR: 216.0-298.0] (p < 0.00000001). At 12 months VA was 50.5 [IQR: 38.5-68.0] (p = 0.0004 vs baseline) and CRT 251.5 m [IQR: 207.5-282.5] (p < 0.0001). Adverse events included 6 IOI cases, with discontinuation in 9 eyes overall. Conclusion Switching to brolucizumab reduced CRT, modestly improved or stabilized VA, and decreased injection frequency with acceptable safety. Limitations include retrospective design, modest sample size, and exclusion of poor visual outcomes, potentially introducing selection bias.
ER  -

HEJSEK, Libor; Michal HREVUS; Maria BUROVA; David BERAN; Zuzana CYZOVA; Martin PENCAK; Tereza PAŘILOVÁ; Dana LILAKOVA a Miroslav VEITH. Efficacy and Safety of Switching from Ranibizumab to Brolucizumab in Age-Related Macular Degeneration: Multicenter Real-World Outcomes. Online. \textit{CLINICAL OPHTHALMOLOGY}. ALBANY: DOVE MEDICAL PRESS LTD, 2025, roč.~19, s.~3729-3740. Dostupné z: https://doi.org/10.2147/OPTH.S543921.

Přehled o publikaci